New merchandise assist pets’ emotional well being and allergic responses, hit market in Taiwan following profitable launch of VELDONA® Pet
Expanding VELDONA® Pet product line builds progress momentum towards US$20M gross sales goal for 2024
SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos”, or the “Company”), a diversified medtech firm targeted on the event of novel point-of-care testing, low-dose interferon therapeutics, and artificial RNA-driven preventative medication, right this moment introduced the launch of two new additions to its VELDONA® Pet cytoprotein complement product line. VELDONA® Pet Lohas, designed to assist pets’ emotional well being and relieve stress, and VELDONA® Pet Soothing, formulated to alleviate discomfort brought on by allergy symptoms, might be launched in Taiwan in July. Ainos goals for US$20 million in gross sales from its VELDONA® Pet dietary supplements throughout 2024, with further product releases and enlargement of gross sales and advertising in different areas.
VELDONA® Pet Lohas contributes to the emotional well-being of dogs and cats, offering reduction from stress and discomfort. A examine performed by China Medical University demonstrated that interferon remedies could cut back the danger of melancholy by aiding within the regulation of mobile inflammatory responses within the mind. Interferon might also positively have an effect on the regeneration and transforming of synapses between nerve cells within the mind.
VELDONA® Pet Soothing normalizes a pet’s immune response to allergens by inducing the physique’s pure regulation mechanism. The product is designed to cut back discomfort and milder allergic signs. The effectiveness of interferons in regulating allergic reactions has been present in a examine performed by the National Research Institute of Japan.
Both dietary supplements might be marketed in Taiwan starting subsequent month. Their launch follows carefully on the heels of final week’s launch of Ainos’ VELDONA® Pet cytoprotein well being complement, which is at the moment available to pet homeowners in Taiwan. Ainos plans to introduce its portfolio of pet merchandise to further markets within the close to future as a part of its world business growth technique.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “The launch of our latest VELDONA® Pet dietary supplements is a crucial milestone on this actually transformational yr for Ainos. Diversifying our product portfolio makes our firm stronger and paves the best way for our future progress and growth. With every new launch, we’re giving pet homeowners further choices to make sure the well being of their companions and positioning ourselves to seize a profitable share of the rising pet well being market.”
“With our more and more strong product portfolio and the deliberate introduction of our present choices to markets all over the world, we’re building a wonderful basis for our goal of US$20 million in gross sales of our VELDONA® Pet dietary supplements in 2024,” Mr. Tsai added. “The second half of 2023 might be an exhilarating time for Ainos as we proceed to work tirelessly in the direction of this aim. I’m extremely pleased with our staff’s drive and execution as we relentlessly pursue the evolution of our business.”
About VELDONA® Pet
Based on Ainos’ low-dose oral interferon-alpha (“IFNα”) formulation, VELDONA® Pet cytoprotein dietary supplements are backed by quite a few analysis research and scientific trials, and are manufactured with world-class supplies in a extremely licensed food-grade plant. VELDONA® maintains immunity and contributes to gum and pores and skin well being, relieving allergy symptoms and decreasing stress in cats and dogs. Interferon, a kind of cytoprotein, is of course produced by human and animals. When cells are invaded by international particles, immune signaling molecules notify neighboring cells. Once neighboring cells obtain the interferon’s protein sign via their floor receptors, they provoke and modulate the immune system to guard felines and canines from gum and pores and skin illnesses, allergy symptoms, and stress-related circumstances.
A scientific examine, sponsored by Ainos and performed by the Agricultural Technology Research Institute in Taiwan, has demonstrated that VELDONA® helps preserve the immune techniques of cats and dogs. Numerous research have reported the advantages of interferons in sustaining gum well being and pores and skin well being, relieving discomfort brought on by allergy symptoms, and soothing emotional stress in cats and dogs. VELDONA® Pet’s mission is to take care of immunity for thousands and thousands of pets with the highest-quality merchandise.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech firm engaged in growing revolutionary medical applied sciences for point-of-care testing and protected and novel medical remedy for a broad vary of illness indications. In addition to its proprietary therapeutics utilizing low-dose non-injectable interferon, Ainos has additionally expanded its product portfolio to incorporate Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT candidate, Ainos Flora, is a telehealth-friendly POCT for girls’s well being and sure frequent STIs. To be taught extra, go to https://www.ainos.com.
Follow Ainos on Twitter (@AinosInc) and LinkedIn to remain up-to-date.
Forward-Looking Statements
This press launch accommodates “forward-looking statements” about Ainos throughout the that means of the protected harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements might be recognized by means of phrases similar to “anticipate,” “consider,” “estimate,” “count on,” “intend,” “plan,” “predict,” “challenge,” “goal,” “future,” “seemingly,” “technique,” “foresee,” “could,” “steerage,” “potential,” “outlook,” “forecast,” “ought to,” “will” or different comparable phrases or phrases. Similarly, statements that describe the Company’s targets, plans or targets are, or could also be, forward-looking statements. Forward-looking statements are primarily based solely on the Company’s present beliefs, expectations, and assumptions. Forward-looking statements are topic to inherent uncertainties, dangers, and modifications in circumstances which might be troublesome to foretell and lots of of that are outdoors of the Company’s management. The Company’s precise outcomes could differ materially from these indicated within the forward-looking statements.
Important elements that would trigger the Company’s precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch embrace, amongst others, the cost of manufacturing and gross sales potential of the deliberate drug remedies introduced on this press launch; the Company’s dependence on revenues from the sale of COVID-19 check kits; the Company’s restricted money and historical past of losses; the Company’s means to realize profitability; the Company’s means to boost further capital to proceed the Company’s product growth; the flexibility to precisely predict the long run working outcomes of the Company; the flexibility to advance Ainos’ present or future product candidates via scientific trials, acquire advertising approval and in the end commercialize any product candidates the Company develops; the flexibility to acquire and preserve regulatory approval of Ainos product candidates; delays in finishing the event and commercialization of the Company’s present and future product candidates, which may end in elevated prices to the Company, delay or restrict the flexibility to generate income and adversely have an effect on the business, monetary situation, outcomes of operations and prospects of the Company; intense competitors and quickly advancing know-how within the Company’s trade which will outpace its know-how; buyer demand for the services the Company develops; the impression of aggressive or various merchandise, applied sciences and pricing; disruption in analysis and growth services; lawsuits and different claims by third events or investigations by varied regulatory companies governing the Company’s operations; potential cybersecurity assaults; elevated necessities and prices associated to cybersecurity; the Company’s means to appreciate the advantages of third occasion licensing agreements; the Company’s means to acquire and preserve mental property safety for Ainos product candidates; compliance with relevant legal guidelines, rules and tariffs; and the Company’s success in managing the expansion. A extra full description of those threat elements and others is included within the “Risk Factors” part of Ainos’ most recent Annual Report on Form 10-Okay and different experiences filed with the U.S. Securities and Exchange Commission, lots of which dangers are past the Company’s management. In addition to the dangers described above and within the Company’s Form 10-Okay, different unknown or unpredictable elements additionally may trigger precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch.
The forward-looking statements made on this press launch are expressly certified of their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking assertion to replicate modified assumptions, the prevalence of anticipated or unanticipated occasions or modifications to the long run outcomes over time or in any other case, besides as required by regulation.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: [email protected]
SOURCE: Ainos, Inc.
